



► PHARMA POOL

Dr. Julie Gerberding MERCK STRENGTHENS EXECUTIVE TEAM



Dr. Julie Gerberding

Merck has named Julie Gerberding, M.D., as executive VP for strategic communications, global public policy and population health. In this newly created executive committee position, Dr. Gerberding, who most recently served as president of Merck Vaccines, is responsible for Merck's global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Dr. Gerberding is also leading new partnership initiatives that accelerate Merck's ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.

► BIOTECH POOL

Dr. Jeremy Graff BIOTHERA NAMES SENIOR VP OF PHARMACEUTICAL RESEARCH



Dr. Jeremy Graff

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer, has appointed Jeremy Graff, Ph.D., as senior VP, research, for its pharmaceutical group. Most recently, Dr. Graff served as a research fellow and group leader, oncology patient tailoring, at Eli Lilly and Company.

William Hodder PROTAGONIST THERAPEUTICS NAMES SENIOR VP, CORPORATE DEVELOPMENT



William Hodder

Protagonist Therapeutics, a biotechnology company engaged in the discovery and development of orally stable peptides for inflammatory bowel diseases (IBD) and other gastrointestinal diseases and disorders, has appointed William Hodder as senior VP, corporate development.

Mr. Hodder joins the company with more than 28 years of experience in the pharmaceutical and biotechnology industry.

Mr. Hodder joins Protagonist from his own consulting practice, where he has assisted both private and public biotech companies with fundraising, business development, and marketing activities.

► DISCOVERY POOL

Dr. Deborah Law JOUNCE THERAPEUTICS APPOINTS CHIEF SCIENTIFIC OFFICER



Dr. Deborah Law

Jounce Therapeutics, a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, has appointed Deborah Law, D.Phil., to the position of chief scientific officer. Dr. Law brings to Jounce almost two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology.

Dr. Law joins Jounce from Merck, where she most recently served as VP of therapy area biology for immunology, oncology, and immunomodulators. In this role, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic.

► AGENCY POOL

Dane Hartung PULSECX NAMES STRATEGIC ACCOUNT LEAD



Dane Hartung

PulseCX has named Dane Hartung senior VP account and strategy. During his 24-year career, Mr. Hartung has worked in global roles supporting in-line and life-cycle products at Merck and within different operating companies at J&J, establishing strategic planning processes, forecasting, customer segmentation, and implementation for new and existing products as well as new indications.

As strategic account lead at PulseCX, Mr. Hartung is responsible for driving internal and external cross-functional teams and leveraging opportunities to strengthen strategic dialogues that uncover the emotional decisions that customers make about brands.

Ann Kottcamp Helen West MMG NAMES PRESIDENT AND COO

MMG, a global full-service patient recruitment group that is part of Ketchum, has promoted Ann Kottcamp to chief operating officer from VP of client services. Since she joined MMG in 2010, Ms. Kottcamp has used her 20 years of experience in patient recruitment to build upon the strengths of MMG's program delivery teams and elevate their capabilities. In her new role, Ms. Kottcamp is charged with looking strategically across the company to maximize performance and client value.



Ann Kottcamp



Helen West

In other company news, Helen West has been named president. She succeeds John Benbrook, who is departing MMG to become CEO of a Pennsylvania-based publishing company. Ms. West, whose most recent role was VP of strategic development, is a pharmaceutical industry veteran with more than 20 years of experience in clinical research. Ms. West joined MMG in 2005 as general medicine therapeutic lead, developing and executing global patient recruitment and retention programs across indications and patient populations.

► CRO POOL

Dr. John Hubbard

BIOCLINICA NAMES CEO



Dr. John Hubbard

BioClinica, a provider of specialty outsourced clinical trial services, has named John Hubbard, Ph.D., as CEO and a member of the board of directors. A seasoned pharmaceutical executive, Dr. Hubbard, joins the company from Pfizer, where he served as senior VP and worldwide head of development operations. Dr. Hubbard assumes the CEO position from Mark Weinstein.

► TECHNOLOGY POOL

John Musante CLINVERSE NAMES CHIEF COMMERCIAL OFFICER



John Musante

Clinverse, a provider of automated financial management technology solutions for clinical trials, has appointed John Musante as chief commercial officer. He brings more than 25 years of experience across industry sectors, including healthcare, technology, and life sciences. Before joining Clinverse, Mr. Musante served as senior VP, business development, at INC Research, where he led a team of account executives. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0215-Pool



► BIOTECH POOL

Dr. Eric Crombez Stephanie Haller DIMENSION THERAPEUTICS EXPANDS LEADERSHIP TEAM

Dimension Therapeutics, a gene therapy company advancing novel treatments for hemophilia and rare diseases, has named Eric Crombez, M.D., as chief medical officer, a newly created position. Most recently, he was senior medical director, global clinical development, at Shire Plc. Dr. Crombez is charged with leading Dimension's team advancing the company's development pipeline of novel gene therapy candidates into clinical testing.

In addition, Dimension appointed Stephanie Haller to the newly created position of VP of clinical operations. Most recently, she was Shire's director, clinical programs, early phase development.

Dr. Jon Hopper OSIRIS THERAPEUTICS EXPANDS LEADERSHIP TEAM

Osiris Therapeutics, a cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics, and sports medicine, has appointed Dr. Jon Hopper as chief medical officer.

Dr. Hopper most recently worked at Stryker Corp., serving as VP, global medical director, where he coordinated clinical evaluation and trials, and provided guidance on clinical aspects of risk management, design control, and product development.

Dr. Peter Mueller PRONUTRIA APPOINTS PRESIDENT OF R&D AND CHIEF SCIENTIFIC OFFICER

Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, has appointed Peter Mueller, Ph.D., as president of research and development and chief scientific officer. Dr. Mueller is responsible for leading Pronutria's efforts to discover and develop products to maintain health and treat a variety of serious medical conditions across a wide spectrum of indication areas including skeletal muscle, metabolic, gastrointestinal, neurodegenerative, and rare diseases.

Before Pronutria, Dr. Mueller was the executive VP of global research and development and chief scientific officer for Vertex Pharmaceuticals, where he provided strategic oversight for Vertex's worldwide drug discovery and development programs, with specific emphasis in Hepatitis C, cystic fibrosis, immune-mediated inflammatory diseases, cancer, and neurological diseases.

Ronald Renaud Jr. RANA THERAPEUTICS APPOINTS CEO

RaNA Therapeutics, a leader in discovering and developing drugs to improve health for patients by

targeting long non-coding RNA to selectively activate protein expression, has appointed Ronald Renaud, Jr., as CEO. Mr. Renaud most recently served as the president and CEO at Idenix Pharmaceuticals until its acquisition by Merck in August 2014.

► BIOPHARMA POOL

Dr. Theodore Ashburn DICERNA ADDS TO SENIOR LEADERSHIP

Dicerna Pharmaceuticals, a developer of RNAi-based therapeutics, has appointed Theodore (Ted) T. Ashburn, M.D., Ph.D., as senior VP, product strategy and operations. Dr. Ashburn brings 15 years of product and corporate development experience to Dicerna. In this newly created position, Dr. Ashburn is charged with leading product strategy and operational efforts for the company's Dicer substrate short interfering RNAi (DsiRNA) therapeutics.

Dr. Ashburn spent the last eight years at Genzyme/Sanofi Oncology where he most recently led all aspects of the marketed product Leukine, including commercial, manufacturing, and development across multiple therapeutic areas and divisions.

John Freshley Linda Johnson Dr. David Kleinman Dr. David Zacks

ONL THERAPEUTICS ADDS TO MANAGEMENT TEAM

ONL Therapeutics, a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has made several management team appointments designed to strengthen the company's leadership as it continues advancement of its novel photoreceptor protection technology.

John Freshley assumes an expanded role as president and chief executive officer, while Linda Johnson takes on the role of senior VP of operations, bringing significant industry experience to ONL in the area of ocular drug development. Additionally, the company has appointed David Kleinman, M.D., as chief medical officer and David Zacks, M.D., Ph.D., one of the company's founders, is transitioning from president and chief medical officer to become the company's chief science officer.

Dr. Stephen Harrison RELYPSA APPOINTS SENIOR VP AND CHIEF SCIENTIFIC OFFICER

Stephen Harrison, Ph.D., has joined Relypsa as senior VP and chief scientific officer. Dr. Harrison, a biochemist and molecular biologist, is highly published and has extensive experience leading product-driven research organizations at all stages, from target identification to early clinical development.

Before joining Relypsa, Dr. Harrison was VP, research biology at Nektar Therapeutics.

Joseph Lobacki MEDIVATION NAMES CHIEF COMMERCIAL OFFICER

Joseph Lobacki joins Medivation as chief commercial officer. In this position, Mr. Lobacki is leading the commercial development strategy, including the marketing and sales functions.

Mr. Lobacki brings almost 30 years of experience in marketing, operations, sales, and medical affairs at major pharmaceutical companies. Most recently, Mr. Lobacki served as the general manager of the oncology business at Idera Pharmaceuticals.

Vincent Milano IDERA PHARMACEUTICALS NAMES CEO

Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, has appointed Vincent Milano as CEO.

Mr. Milano previously served as chairman, president, and CEO of ViroPharma, where he led the building of an international organization with multiple products for the treatment of patients with rare diseases. Mr. Milano succeeds Sudhir Agrawal, D.Phil., who continues to lead scientific research as president of research and serves on Idera's board.

Dr. Barbara Troupin APRICUS BIOSCIENCES APPOINTS CHIEF MEDICAL OFFICER

Apricus Biosciences, a biopharmaceutical company advancing innovative medicines in urology and rheumatology, has appointed Barbara Troupin, M.D., as the chief medical officer. Dr. Troupin brings to Apricus more than 15 years of experience in the areas of pharmaceutical clinical development and medical affairs.

Since 2006, Dr. Troupin has held various senior management roles with Vivus in the areas of medical affairs and clinical development. In these roles, Dr. Troupin was the clinician lead for the Phase III program for Qsymia.

► SPECIALTY POOL

Keith Kendall Mark Schobel MONSOL RX ADDS TO MANAGEMENT TEAM

MonoSol Rx, the developer of PharmFilm drug delivery technology, has named Keith Kendall as CEO and Mark Schobel as chief innovation and technology officer, a newly created position.

Mr. Kendall, who was promoted from chief operating officer, will oversee the execution of the company's growth strategy.

In his new role, Mr. Schobel, who joined the

company as CEO in 2005, is charged with leading the company's intellectual property strategy and internal technology development initiatives to further advance MonoSol Rx's PharmFilm drug delivery technology.

► GENOMICS POOL

Patrick Terry CLARITAS GENOMICS APPOINTS CHIEF COMMERCIAL OFFICER

Claritas Genomics has appointed Patrick Terry to the role of chief commercial officer. Mr. Terry, chairman of Gray Group Ventures Ltd., and a founder of Genomic Health, has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery. Mr. Terry is charged with building Claritas's commercial organization to expand the company's reach to pediatric hospitals and patients and ensure that the Claritas services also meet the needs of payers.

► AGENCY POOL

David Bashaw HEALTHSTAR PR NAMES EXECUTIVE VP

HealthStar PR, a specialty healthcare public relations firm and a division of HealthStar Communications, has appointed industry veteran David Bashaw as executive VP. Mr. Bashaw is responsible for helping manage the agency during this time of significant growth, as well as ensuring that clients continue receiving unrivaled client service, strategic thinking, and executional excellence.

Dr. Jo Pearson SUDLER & HENNESSEY APPOINTS NEW HEAD OF MEDICAL COMMUNICATIONS

Sudler & Hennessey, a global healthcare communications company, has named Jo Pearson, M.D., an experienced medical education and communications as head of S&H Medical Communications.

Dr. Pearson established her career working for agencies such as MediTech Media and Virgo Health. Her background is in academic research and she obtained her Ph.D. from the University of Oxford studying immune mechanisms in inflammatory disease. In her new role, she is responsible for managing the team and continuing to drive growth in the medical communications sector.

► TECHNOLOGY POOL

Paul Argay AMC HEALTH NAMES CHIEF MARKETING OFFICER

AMC Health, a provider of virtual patient moni-

toring and engagement solutions that advance monitored care in healthcare and clinical trial categories, has named Paul Argay as chief marketing officer. Mr. Argay comes to the company with more than 25 years experience in marketing leadership positions and a consistent track record of launching and building businesses in product

and service companies, large and small. During his career, he has helped build and grow successful consumer products, wireless communications, and healthcare IT brands.

Most recently, he was chief marketing officer at Resolution Health, a healthcare IT start-up that was acquired by WellPoint. **PV**

ePharma

February 24–26, 2015
Hilton New York Midtown
New York, NY

BUY ONE GET ONE FREE*

Challenge your mindset with unique perspectives and tech to disrupt your strategy and drive ROI

Here's what's new in 2015...

- Tackle the 7 Critical Trends** that will make or break your digital strategy
- Collaboration Arena** where candid and fluid conversations flow for knowledge exchange
- Immersive Wearables Lounge** to enhance patient outcomes with "pill-plus" technology
- Patient Room 2020 Expedition** so you can plan for the future customer experience
- 70% New Speakers** for the freshest insights

Digital marketing is exploding as it drives your marketing strategies to the next level. ePharma provides the roadmap for you to:

- Boost** prescriptions
- Increase** patient adherence
- Grow** patient demand
- Strengthen** HCP engagement and recall
- Decrease** sales costs
- And more!**
- Optimize** spend

[@epharma #ePharma](#) [f ePharma Summit](#) [in ePharma Summit](#) [ePharmaSummitBlog.com](#)

* This offer is only valid for individuals in the pharmaceutical industry and new registrants. This offer is cannot be applied retroactively to confirmed paying registrants and cannot be combined with any other discounts or promotions. All registrants are subject to IIR approval.

Bring your marketing buddy at no additional charge—It's like **50% off each person!**
Register today at epharmasummit.com or (888) 670-8200